Actelion, Europe’s largest biotech company, confirmed its full-year outlook on Thursday ahead of a widely anticipated approval of its big drug hope Opsumit by U.S. health regulators later this week. Nine month sales of its main product Tracleer, a treatment for pulmonary arterial hypertension (PAH), rose 3 percent to 1.138 billion Swiss francs ($1.24 billion). Net profit was 105 million francs in the third quarter, beating analysts’ forecasts of 88.5 million.
Help employers find you! Check out all the jobs and post your resume.
